Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in sales revenue and improvements in gross profit for Q3 2024, alongside increased operating expenses and a net loss attributable to common shareholders. Financial Highlights - Q3 2024 sales revenue increased 164% year-over-year to approximately $135 thousand from $51 thousand in Q3 2023 [3] - ARAKODA® pharmacy deliveries rose by 140% from 550 boxes in Q3 2023 to 1,319 boxes in Q3 2024 [3] - Gross profit improved to approximately $24 thousand in Q3 2024, compared to a gross loss of approximately $20 thousand in Q3 2023 [3] - Operating expenses were approximately $2.16 million in Q3 2024, up from approximately $1.58 million in Q3 2023 [3] - Net loss attributable to common shareholders was approximately $2.27 million, or ($0.93) per share, compared to a net income of approximately $4.09 million, or $9.13 per share in Q3 2023, representing a decline of $6.36 million [3] Business Highlights - The Company granted the University of Kentucky the right of reference to its NDA for ARAKODA®, facilitating FDA review of clinical efficacy and safety data [4] - A fixed-price contract was awarded to support commercial validation of new packaging for ARAKODA® by the United States Army Medical Materiel Development Activity [4] - Ethics approval was granted for an open label, expanded access study of ARAKODA® in immunosuppressed patients with persistent/relapsing babesiosis [4] - Clinical trial agreements were signed with all planned trial sites for the Tafenoquine Babesiosis Study [4] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing and marketing new medicines for infectious diseases and achieved FDA approval for ARAKODA® in 2018 [5] - The Company collaborates with prominent research organizations in the U.S., Australia, and Singapore, and has received support from the U.S. Department of Defense and private institutional investors [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | --- | - ...

Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs. ARAKODA is the only new antimalarial in over a decade and is differentiated by a broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile. WASHINGTON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; S ...

60 Degrees Pharmaceuticals Inc. (SXTP) came out with a quarterly loss of $4.23 per share versus the Zacks Consensus Estimate of a loss of $3.96. This compares to loss of $16.81 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -6.82%. A quarter ago, it was expected that this company would post a loss of $1.92 per share when it actually produced earnings of $0.36, delivering a surprise of 118.75%. Over the last four quarters, th ...

Q2 2024 net product revenues doubled year-over-year to $125 thousand Sequential (quarter-over-quarter) net product revenue growth of 18.3% Gross profit increased from ($124 thousand) to $35 thousand, year-over-year WASHINGTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the second quarter of 2024, ended June 30, 2024. F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | --- | --- | ...

60 Degrees Pharmaceuticals (NASDAQ:SXTP) stock is gaining on Monday after the specialty pharmaceutical company announced an agreement with the University of Kentucky. This agreement will have the University of Kentucky conducting a Phase IIb clinical trial of SJ733. This is a drug candidate in development by 60 Degrees Pharmaceuticals for the treatment of vivax malaria. This study will cover the use of SJ733 alongside tafenoquine to treat vivax malaria. The information from this study will also be applied t ...

University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the study. The right of reference allows FDA to review 60 Degrees Pharma's regulatory file when the agency evaluates new study protocols for the SJ733-tafenoquine Phase IIb program. WASHINGTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company" or "60 Degrees Pharma" ...

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share ("Common Stock"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SXTP" and will begin trading on a split-adjusted basis ...

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share ("Common Stock"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SXTP" and will begin trading on a split-adjusted basis ...